BioCentury | Jan 2, 2012
Company News

HistoRx, Yale University deal

The university granted HistoRx rights to an assay that identifies melanoma patients who have a 40% risk of recurrence of the disease despite having no detectable cancer in their lymph nodes. The assay is based...
BioCentury | Dec 5, 2011
Company News

PerkinElmer sales and marketing update

PerkinElmer's Caliper company launched Vectra 2 with AQUA technology in North America, Asia and Europe. Caliper partnered with HistoRx Inc. (New Haven, Conn.) in March to develop the immuno-fluorescence imaging technology to measure proteins in...
BioCentury | Mar 14, 2011
Company News

Caliper, HistoRx deal

Caliper and HistoRx partnered to develop a tissue-based immuno-fluorescence imaging technology to measure proteins in tissue samples. The product will combine Caliper's Vectra automated multiplexed tissue imaging technology with HistoRx's AQUA fluorescent immunohistochemistry technology. Caliper,...
BioCentury | Jan 3, 2011
Company News

HistoRx, Metamark Genetics deal

Metamark received worldwide rights to HistoRx's AQUA fluorescent immunohistochemistry technology to commercialize Metamark's MetamarkDx Prognostic Assays. The assays identify patient tumor profiles through quantitative expression analysis of Metamark's Prognosis Determinants. Further terms were not disclosed....
BioCentury | Nov 22, 2010
Company News

Genoptix, HistoRx sales and marketing update

Genoptix launched NexCourse BCa by AQUA technology in the U.S. The tests are for confirmatory estrogen receptor, progesterone receptor , and EGF receptor 2 ( HER2 ; ErbB2 ; neu) status prior to hormonal or antibody-based therapy...
BioCentury | Mar 1, 2010
Company News

Genoptix, HistoRx deal

Genoptix received an exclusive, U.S. license to use HistoRx's AQUA technology to develop and commercialize three solid tumor assays. AQUA is used to quantify biomarkers in tissue. Genoptix also received non-exclusive rights to use AQUA...
BioCentury | Jul 21, 2008
Company News

HistoRx management update

HistoRx Inc. , New Haven, Conn. Business: Diagnostic Hired: William Sullivan as SVP of diagnostic operations, formerly VP of corporate operations at Vermillion Inc. (formerly Ciphergen Biosystems Inc. ) WIR Staff Diagnostic...
BioCentury | Mar 31, 2008
Company News

HistoRx, Eli Lilly deal

Under an expansion of a 2005 deal, Lilly received the right to use HistoRx's Aqua fluorescence-based imaging technology for tissue biomarker analysis in undisclosed R&D programs, and HistoRx will develop customized immunohistochemical assays for Lilly...
BioCentury | Dec 3, 2007
Company News

HistoRx management update

HistoRx Inc. , New Haven, Conn. Business: Diagnostic Transitioned: Rana Gupta to CEO from interim CEO WIR Staff Diagnostic...
BioCentury | Dec 3, 2007
Company News

HistoRx board of directors update

HistoRx Inc. , New Haven, Conn. Business: Diagnostic Appointed: Gregory Gardiner, a director, as chairman; and Seth Feuerstein, president of Carigent Therapeutics Inc. WIR Staff...
Items per page:
1 - 10 of 17
BioCentury | Jan 2, 2012
Company News

HistoRx, Yale University deal

The university granted HistoRx rights to an assay that identifies melanoma patients who have a 40% risk of recurrence of the disease despite having no detectable cancer in their lymph nodes. The assay is based...
BioCentury | Dec 5, 2011
Company News

PerkinElmer sales and marketing update

PerkinElmer's Caliper company launched Vectra 2 with AQUA technology in North America, Asia and Europe. Caliper partnered with HistoRx Inc. (New Haven, Conn.) in March to develop the immuno-fluorescence imaging technology to measure proteins in...
BioCentury | Mar 14, 2011
Company News

Caliper, HistoRx deal

Caliper and HistoRx partnered to develop a tissue-based immuno-fluorescence imaging technology to measure proteins in tissue samples. The product will combine Caliper's Vectra automated multiplexed tissue imaging technology with HistoRx's AQUA fluorescent immunohistochemistry technology. Caliper,...
BioCentury | Jan 3, 2011
Company News

HistoRx, Metamark Genetics deal

Metamark received worldwide rights to HistoRx's AQUA fluorescent immunohistochemistry technology to commercialize Metamark's MetamarkDx Prognostic Assays. The assays identify patient tumor profiles through quantitative expression analysis of Metamark's Prognosis Determinants. Further terms were not disclosed....
BioCentury | Nov 22, 2010
Company News

Genoptix, HistoRx sales and marketing update

Genoptix launched NexCourse BCa by AQUA technology in the U.S. The tests are for confirmatory estrogen receptor, progesterone receptor , and EGF receptor 2 ( HER2 ; ErbB2 ; neu) status prior to hormonal or antibody-based therapy...
BioCentury | Mar 1, 2010
Company News

Genoptix, HistoRx deal

Genoptix received an exclusive, U.S. license to use HistoRx's AQUA technology to develop and commercialize three solid tumor assays. AQUA is used to quantify biomarkers in tissue. Genoptix also received non-exclusive rights to use AQUA...
BioCentury | Jul 21, 2008
Company News

HistoRx management update

HistoRx Inc. , New Haven, Conn. Business: Diagnostic Hired: William Sullivan as SVP of diagnostic operations, formerly VP of corporate operations at Vermillion Inc. (formerly Ciphergen Biosystems Inc. ) WIR Staff Diagnostic...
BioCentury | Mar 31, 2008
Company News

HistoRx, Eli Lilly deal

Under an expansion of a 2005 deal, Lilly received the right to use HistoRx's Aqua fluorescence-based imaging technology for tissue biomarker analysis in undisclosed R&D programs, and HistoRx will develop customized immunohistochemical assays for Lilly...
BioCentury | Dec 3, 2007
Company News

HistoRx management update

HistoRx Inc. , New Haven, Conn. Business: Diagnostic Transitioned: Rana Gupta to CEO from interim CEO WIR Staff Diagnostic...
BioCentury | Dec 3, 2007
Company News

HistoRx board of directors update

HistoRx Inc. , New Haven, Conn. Business: Diagnostic Appointed: Gregory Gardiner, a director, as chairman; and Seth Feuerstein, president of Carigent Therapeutics Inc. WIR Staff...
Items per page:
1 - 10 of 17